Detalles de la búsqueda
1.
Effectiveness of tacrolimus concomitant with biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
Mod Rheumatol
; 33(2): 292-301, 2023 Mar 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35289372
2.
Reasons and risk factors for discontinuation of treatment with any biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: A long-term observational study.
Mod Rheumatol
; 33(5): 891-898, 2023 Aug 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-35975317
3.
Higher doses of methotrexate associated with discontinuation of oral glucocorticoids after initiation of biological DMARDs: A retrospective observational study based on data from a Japanese multicenter registry study.
Mod Rheumatol
; 31(4): 796-802, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33492191
4.
Improvement in matrix metalloproteinase-3 independently predicts low disease activity at 52 weeks in bio-switch rheumatoid arthritis patients treated with abatacept.
Clin Exp Rheumatol
; 38(5): 933-939, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32083543
5.
Discontinuation of concomitant methotrexate in Japanese patients with rheumatoid arthritis treated with tocilizumab: An interventional study.
Mod Rheumatol
; 30(3): 434-441, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-31390271
6.
Clinical effectiveness and long-term retention of abatacept in elderly rheumatoid arthritis patients: Results from a multicenter registry system.
Mod Rheumatol
; 29(6): 910-918, 2019 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-30220237
7.
High rate of improvement in serum matrix metalloproteinase-3 levels at 4 weeks predicts remission at 52 weeks in RA patients treated with adalimumab.
Mod Rheumatol
; 28(1): 119-125, 2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-28463029
8.
Predictors of biologic discontinuation due to insufficient response in patients with rheumatoid arthritis who achieved clinical remission with biologic treatment: A multicenter observational cohort study.
Mod Rheumatol
; 28(2): 221-226, 2018 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-28701065
9.
Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study.
Rheumatology (Oxford)
; 54(1): 113-20, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25102861
10.
Use of a 12-week observational period for predicting low disease activity at 52 weeks in RA patients treated with abatacept: a retrospective observational study based on data from a Japanese multicentre registry study.
Rheumatology (Oxford)
; 54(5): 854-9, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25339638
11.
Concomitant methotrexate and tacrolimus augment the clinical response to abatacept in patients with rheumatoid arthritis with a prior history of biological DMARD use.
Rheumatol Int
; 35(10): 1707-16, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25991396
12.
Drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors for rheumatoid arthritis in Japanese patients on low-dose methotrexate or without methotrexate.
Mod Rheumatol
; 25(2): 251-6, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25211402
13.
Comparison of efficacy and safety of tacrolimus and methotrexate in combination with abatacept in patients with rheumatoid arthritis; a retrospective observational study in the TBC Registry.
Mod Rheumatol
; 25(6): 825-30, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25775147
14.
A review of tocilizumab treatment in 122 rheumatoid arthritis patients included in the Tsurumai Biologics Communication Registry (TBCR) Study.
Mod Rheumatol
; 23(2): 245-53, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22526833
15.
Clinical efficacy of abatacept in Japanese rheumatoid arthritis patients.
Mod Rheumatol
; 23(5): 904-12, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-22975734
16.
Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis.
Mod Rheumatol
; 23(5): 977-85, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23099471
17.
Early aggressive intervention with tocilizumab for rheumatoid arthritis increases remission rate defined using a Boolean approach in clinical practice.
Mod Rheumatol
; 22(3): 370-5, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21931942
18.
Study protocol of a multicenter registry of patients with rheumatoid arthritis starting biologic therapy in Japan: Tsurumai Biologics Communication Registry (TBCR) study.
Mod Rheumatol
; 22(3): 339-45, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21892671
19.
Comparison of the effects of baricitinib and tocilizumab on disease activity in patients with rheumatoid arthritis: a propensity score matching analysis.
Clin Rheumatol
; 40(8): 3143-3151, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34136969
20.
Predictors for clinical effectiveness of baricitinib in rheumatoid arthritis patients in routine clinical practice: data from a Japanese multicenter registry.
Sci Rep
; 10(1): 21907, 2020 12 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-33318522